A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemo - globinuria terminated by treatment with eculizumab

Thrombosis and Haemostasis

Volumn 106, Issue 2, 2011, Pages 384-385

  Schutgens, Roger E G ^a   Pruissen Peeters, Kim A B M ^b   Muus, Petra ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; CLOPIDOGREL; DANAPAROID; ECULIZUMAB; FLUCLOXACILLIN; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENPROCOUMON; TIROFIBAN; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; ADULT; APLASTIC ANEMIA; ARTHRALGIA; BLEEDING TIME; BLISTER; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CORONARY STENT; DEEP VEIN THROMBOSIS; ECCHYMOSIS; FEMALE; FEVER; HEART INFARCTION; HEMOLYSIS; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LUNG EMBOLISM; MICROTHROMBUS; PANCYTOPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PURPURA; RETICULOCYTOPENIA; SKIN BIOPSY; THROMBOCYTE COUNT; THROMBOEMBOLISM; HUMAN PARVOVIRUS B19; MIDDLE AGED; PARVOVIRUS INFECTION; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT INACTIVATING AGENTS; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; RECURRENCE; THROMBOEMBOLISM;

EID: 79961076150     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-03-0165     Document Type: Letter

References (22)

1. Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994; 330: 249-255.
2. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-. Blood 2006; 107: 1308-1314.
3. de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008; 112: 3099-3106.
4. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003; 102: 3587-3591.
5. Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348: 573-577.
6. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243.
7. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 1840-1847.
8. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 4123-4128.
9. Abe R, Shichishima T, Ogawa K, et al. Neutropenia due to parvovirus B19 infections in patients with paroxysmal nocturnal hemoglobinuria. Blood transfusion and natural infection cases. Acta Haematol 2006; 116: 245-248.
10. Kok RH, Wolfhagen MJ, Klosters G. A syndrome resembling thrombotic thrombocytopenic purpura associated with human parvovirus B19 infection. Clin Infect Dis 2001; 32: 311-312.
11. Young NS, Abkowitz JL, Luzzatto L. New Insights into the Pathophysiology of Acquired Cytopenias. Hematology Am Soc Hematol Educ Program 2000, 18-38.
12. Grunewald M, Siegemund A, Grunewald A, et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis 2003, 14: 685-695.
13. Ninomiya H, Hasegawa Y, Nagasawa T, et al. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol 1997; 65: 285-291.
14. Sloand EM, Pfannes L, Scheinberg P, et al. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol 2008; 36: 1616-1624.
15. Gralnick HR, Vail M, McKeown LP, et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 91: 697-702.
16. Wiedmer T, Hall SE, Ortel TL, et al. Complementinduced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993; 82: 1192-1196.
17. Qin X, Hu W, Song W, et al. Balancing role of nitric oxide in complement-mediated activation of platelets from mCd59a and mCd59b double-knockout mice. Am J Hematol 2009; 84: 221-227.
18. Kato GJ, Taylor JG. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol 2010; 148: 690-701.
19. Helley D, de Latour RP, Porcher R, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 2010; 95: 574-581.
20. Ziakas PD, Poulou LS, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol 2008; 6: 347-353.
21. Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-1258.
22. RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009; 113: 6522-6527.